The FDA Oncologic Drugs Advisory Committee will meet Jan. 7, 2015, to discuss a biologics license application for a proposed biosimilar to Amgen Inc.'s Neupogen (filgrastim).
As Congress goes into recess and Democrats relinquish their eight-year control of the Senate, advocates for biomedical research are rethinking their approaches to a political reality not observed in nearly a decade: a Republican-controlled Congress.
The Cancer Letter asked leaders of science and cancer advocacy groups to comment on the half-percent increases in federal funding for NIH and NCI in fiscal 2015, and on the prospects of science funding when Republicans take control of Congress in January.
The 113th Congress staggered through its final spending bill, approving $1.1 trillion in a massive “cromnibus” Dec. 13, keeping most of the federal government funded through September 2015, and locking in a half-percent increase for NIH and NCI in FY2015.
Gregory BontragerGregory Bontrager resigned from his position as chief operating officer and president of the American Cancer Society.
The House Committee on Energy and Commerce is spearheading legislation aimed streamlining development of drugs and medical devices.
DAVID CURROW was named director of palliative medicine and hospice care at the Dartmouth-Hitchcock health system.
BORIS KUVSHINOFF II was named chief medical quality officer and interim chief medical officer at Roswell Park Cancer Institute.
MARCELO BENTO SOARES was named senior associate dean for research at the University of Illinois College of Medicine at Peoria.
WELDON GAGE was named vice president and chief financial officer of MD Anderson Cancer Center, effective Jan. 12, 2015.
